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SUMMARY 
Aspirin depresses thrombin generation, probably through a mechanism independent of the cyclooxygenase inhi-
bition, but rather related to acetylation of the platelet membrane macromolecules. This action of aspirin is
blunted in hypercholesterolemia. In men with marked hypercholesterolemia, lowering serum cholesterol by
a three-month simvastatin treatment is accompanied by a reduction of thrombin generation both at basal con-
ditions in venous blood and after activation of hemostasis by microvascular injury. Similar results are obtained
in patients with coronary heart disease and borderline – high cholesterol levels. We assessed tissue-factor initia-
ted coagulation in blood samples collected every 30-seconds from bleeding time wounds in patients with advan-
ced coronary artery disease and total cholesterol levels of 224 mg/dL. Three-month simvastatin treatment de-
pressed blood clotting, leading to reduced rates of prothrombin activation, FVa generation, fibrinogen cleavage,
FXIII activation, and an increased rate of FVa inactivation. Such a concerted influence of statins on the clot-
ting cascade seems to be independent of their lipid-lowering action and may be the result of depressed isopre-
noid production.
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Clinical trials demonstrated effectiveness of 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, or statins, in primary and se-
condary prevention of coronary artery disease
(CAD). In most reports, these drugs exerted stron-
ger beneficial effects on coronary endpoints than
those anticipated from analysis of the reduction in
total cholesterol (TC) and LDL cholesterol levels
[1]. Over the last years, evidence has accumulated
that inhibition of HMG-CoA reductase result in
pleiotropic, antiatherothrombotic effects, often at-
tributed to the inhibition of isoprenoid production
secondary to inhibition of mevalonic acid synthesis
[2,3]. These properties, which appear to be inde-
pendent of their lipid-lowering activity, include:
stabilization of atherosclerotic plaque [4], suppres-
sion of inflammation [5], impairment of vascular
smooth muscle cell proliferation [6], promotion of
blood vessel growth [7], improved endothelial
function through nitric oxide (NO)-dependent me-
chanisms [8], stimulation of fibrinolysis [9], and po-
orly described modulation of blood coagulation
[3]. Since statins dramatically decrease the inciden-
ce of acute coronary events and ischemic stroke
and the most critical aspect of atherosclerosis from
clinical point of view is plaque rupture and throm-
bus formation in loco, antithrombotic alterations in
the blood coagulation cascade following statin the-
rapy could be expected. Indeed, several studies,
performed mainly in vitro, suggested that statins
can influence directly or indirectly coagulant func-
tions of platelets, blood cells, vascular walls, circu-
lating coagulation factors or cofactors.
Until now, there is great controversy about effects
of statins on platelet function [10,11]. Available da-
ta suggest that statins inhibit platelet-mediated
thrombin generation and its proteolytic activity.
A marked decrease in thrombin generation, as evi-
denced by reductions in plasma thrombin genera-
tion markers, such as prothrombin fragment
(F1+2), fibrinopeptide A (FPA) and thrombin-anti-
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thrombin III complexes (TAT), has been reported in
hypercholesterolemic subjects treated with prava-
statin or simvastatin [12,13]. Some authors showed
a correlation between the magnitude of reduction
in thrombin formation or alteration in platelet
function and hypolipemic effect of statins [14,15].
The nature and characteristics of statin-induced
thrombin-lowering effects are still elusive.
Here, we summarize results of our studies on anti-
thrombotic properties of simvastatin, a potent lipo-
phylic statin.
We observed that aspirin’s antithrombotic action
was blunted in hypercholesterolemic subjects [16],
we decided to investigate the impact of marked re-
duction in TC on this phenomenon. To address this
important issue, we have evaluated the TF-initiated
coagulation at the site of hemostatic plug forma-
tion, in blood obtained from bleeding-time wo-
unds [17]. Since the kinetics of coagulant reactions
in vivo cannot be extrapolated from static systems,
we have chosen a model of microvascular injury,
which offers a unique approach to the physiologi-
cal situation when the damaged vessel wall and
subendothelium are suddenly exposed to circula-
ting blood [18]. We hypothesize that alterations in
the blood coagulation cascade and/or platelet
function, providing catalytic surface for prothrom-
binase formation should be evident in the in vivo
model. When factor (F)VIIa encounters tissue fac-
tor (TF) exposed at the site of injury, they form the
extrinsic tenase, which activates FX and FIX to their
active forms, and then, FXa assembles with FVa in-
to the prothrombinase complex, converting proth-
rombin to thrombin. This multifunctional enzyme
activates cofactors FV and FVIII, thereby amplifying
blood coagulation [19].
We treated 33 symptom-free men with markedly
elevated TC levels (mean, 8.03 mmol/L) and LDL
cholesterol (mean, 5.59 mmol/L) for 12 weeks with
simvastatin (20–40 mg/d), followed by an additio-
nal two-week combined therapy with the statin
and aspirin (300 mg/d). An approximate produc-
tion of thrombin within the first 180 seconds of
bleeding was estimated on the basis of the area un-
der the concentration curve of F1+2 and FPA va-
lues in 30-second intervals. A 3-month simvastatin
therapy resulted in a significant decrease in TC by
31% and LDL-cholesterol by 42%. At sites of mi-
crovascular injury, thrombin generation became
markedly depressed by simvastatin, as evidenced
by reduced initial thrombin concentration and total
amount of the enzyme generated. In venous blo-
od, only FPA levels were decreased. Addition of
aspirin to the statin did not lower thrombin forma-
tion in the model used or venous blood. We, the-
refore, concluded that reduction in blood choleste-
rol concentrations is not able to restore the inhibi-
tory effect of aspirin on thrombin generation to its
magnitude, observed by us previously in normo-
cholesterolemic subjects [20].
These observations in patients with marked hyper-
cholesterolemia prompted a further study in CAD
patients with average cholesterol levels, treated
with low-dose aspirin [21]. In 25 male patients
with stable CAD, with a mean age of 55 years, and
TC levels below 6.5 mmol/L, F1+2 concentrations
were measured in bleeding time blood every 30
seconds. A 3-month simvastatin treatment led
a decrease in the total amount of prothrombin co-
nverted to thrombin by about 50%. This reduction
was accompanied by a significant decrease in TC
from 5.9 to 4.4 mmol/L and LDL cholesterol from
3.7 to 2.2 mmol/L. These reductions did not corre-
late with the magnitude of thrombin-lowering ac-
tion of simvastatin. Moreover, a significant prolon-
gation of bleeding time following simvastatin (by
38 s) has been found. We clearly demonstrated
that thrombin-lowering action of simvastatin are
not limited to marked hypercholesterolemia but
extend to patients with slightly elevated blood cho-
lesterol levels.
In the light of studies showing reduced thrombin
formation following statin therapy, we put forward
a hypothesis that statins may alter FV, FXIII, and
prothrombin activation as well as FVa inactivation
by activated protein C (APC). To provide a com-
prehensive view of simvastatin-induced anticoagu-
lant effects, we studied time-courses of coagulant
reactions pertinent to efficient blood clotting prior
to and after a 3-month simvastatin treatment (20
mg/d). The study population comprised 17 men,
aged 39-64 (mean, 51.6) years, with documented
advanced coronary artery disease and/or stable an-
gina and with average serum TC (mean, 5.8
mmol/L) and LDL cholesterol (mean, 3.6 mmol/L)
levels [22]. Quantitative Western blotting was per-
formed, using antibodies against fibrinogen, FV he-
avy and light chains, the subunit A of FXIII and pre-
thrombin 1, which recognizes, among other, proth-
rombin and thrombin B-chain [23].
Treatment with simvastatin led to significant reduc-
tions in both TC (from 5.8 mmol/L to 4.5 mmol/L)
and LDL cholesterol (from 3.6 mmol/L to 2.3
mmol/L), while triglycerides and HDL-C did not al-
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ter. Interestingly, bleeding time became slightly,
but significantly, prolonged by 37 s. Administration
of simvastatin was associated with potentially favo-
rable alterations in blood coagulation, including
statistically significant decreases in maximum rates
of:
(1) activation of prothrombin (by 13%) and forma-
tion of α-thrombin B-chain (by 25%),
(2) generation of FVa heavy chain (by 30%) and
FVa light chain (by 17%),
(3) fibrinogen conversion to fibrin (by 64%),
(4) factor XIII activation (by 20%).
Changes in the kinetics of all the reactions studied
were accompanied by a significant delay by 30–60 s.
Fibrinopeptide A (FPA) and B (FPB) levels in blood
collected within the last 30 seconds of bleeding
were determined by high pressure liquid chroma-
tography (HPLC), and their identification confir-
med using matrix-assisted laser desorption ioniza-
tion-time flight (MALDI-TOF) mass spectrometry.
Following simvastatin treatment FPA concentration
decreased from 4 µmol/l to 3 µmol/l, whereas le-
vels of FPB, cleaved slowly from the B chains of fi-
brinogen, fell from 0.8 µmol/l to levels below de-
tection limit. This finding confirmed impairment of
thrombin-mediated proteolysis of fibrinogen, as
a result of simvastatin therapy.
Unexpectedly, inactivation of FVa was affected by
simvastatin treatment. There was a significant acce-
leration of a release of the 30 kD fragment of FVa
heavy chain (residues 307-506), a product of FVa
cleavage by APC. This fragment appeared faster –
by 90 s – after treatment with simvastatin. We
concluded that simvastatin treatment may modula-
te the major anticoagulant system in humans, the
protein C pathway, which inactivates FVa and
FVIIIa and shuts down thrombin formation [24]. In
the microvasculature, where thrombomodulin con-
centration is high relative to the blood volume, FVa
degradation occurred much faster than during clot-
ting of the whole blood [23]. Since thrombin gene-
ration was impaired by simvastatin treatment, a fa-
ster appearance of the 30 kD fragment of FVa he-
avy chain is unlikely to result from an increase in
thrombin-mediated protein C activation. It might
be speculated that more rapid FVa inactivation fol-
lowing simvastatin treatment may be related to al-
terations in thrombomodulin expression on the en-
dothelial cells or its cofactor function. It cannot be
excluded that statin-induced impairment of plate-
let function decreases the amount of thrombomo-
dulin released in loco [25]. Acceleration of APC-
-mediated inactivation of a cofactor of prothrombi-
nase, FVa, is likely to contribute largely to antith-
rombotic actions of simvastatin in vivo.
Another important issue is whether antithrombotic
actions of statins are related to their cholesterol-lo-
wering effects. Results of in vitro studies suggest
that atherogenic lipoproteins could enhance
thrombin generation by promoting formation of
the prothrombinase complex [26], however, trigly-
cerides are probably more potent in providing ad-
ditional surface for the assembly of prothrombinase
[27]. Our data strongly argue against any relation-
ship between hypolipemic and antithrombotic ac-
tions of simvastatin because reductions in thrombin
generation or FVa formation showed no relation-
ship with the initial lipid profile and the degree of
serum cholesterol reduction.
It remains to be determined which mechanisms
produce a shift toward anticoagulation in the he-
mostatic balance following a 3-month simvastatin
treatment. Suppression of TF exposure appears to
be a plausible explanation. Retarded and slower
thrombin-mediated FV and FXIII activation appear
to be secondary to posttreatment decrease in
thrombin production. Prolongation of a lag phase
in thrombin generation, which is determined by
a concentration of the initiator of the extrinsic co-
agulation pathway, the complex TF-FVIIa [28], also
suggests statin-induced downregulation of TF
expression in the endothelium and subendothe-
lium. Until now, decreased TF expression, induced
by statins, has been, however, demonstrated solely
on cultured human macrophages or monocytes.
Tissue factor-induced formation of thrombin on
human monocytes, stimulated by lipopolisachary-
des, was significantly decreased by simvastatin at fi-
nal concentrations of 10 nmol/l to 10 µmol/l [29].
A postulated mechanism by which simvastatin mi-
ght change the coagulation reactions is inhibition
of the synthesis of isoprenoids such as farnesyl and
geranylgeranyl pyrophosphates, which are substra-
tes for posttranslational modification – isoprenyla-
tion – of numerous intracellular proteins, including
GTP-binding proteins [30]. Suppression of isopre-
noid production by statins may lead to decreased
expression of TF in the endothelium and/or suben-
dothelium. Decreased TF expression could also be
due to statin-induced upregulation of endothelial
NO synthase [31], leading to an increase in NO
production, which depresses TF expression in the
endothelium [32]. Decreased tumor necrosis factor
(TNF-a) expression by macrophages, which has
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been reported in patients with polygenic hyper-
cholesterolemia after eight weeks of simvastatin
treatment [33], can provide a link between antith-
rombotic and anti-inflammatory actions of statins,
because it is well known that pro-inflammatory cy-
tokines increase the expression of TF.
Fenton et al. [34] attempted to form a coherent
theory based on available data and postulated that
decreased TF expression, combined with the do-
wnregulation in cell signaling following thrombin
activation of protease activated receptor-1 (PAR-1),
may explain antithrombotic properties of HMG-
-CoA reductase inhibitors. They proposed that sta-
tins may constitute a new class of antithrombotic
drugs, possibly effective in patients with a proth-
rombotic tendency of another than atherosclerotic
origin. It should be mentioned that very recently
statins have been found to decrease FVII coagulant
activity in hyperlipidemic patients [35]. A concept
of reduced formation of the TF-FVIIa complexes in
response to statin therapy deserves further studies.
Important remaining issues concerning antithrom-
botic effects of statins pertain to potential differen-
ces between different agents of this class, contribu-
tion of concomitant diseases or coronary risk fac-
tors, including high cholesterol levels, to their pre-
sence and to dose-dependance of these actions.
First, there is no reason to suspect that actions of
pravastatin, atorvastatin or cerivastatin differ from
these observed during treatment with moderate
doses of simvastatin. However, some studies sugge-
sted a differential effect of statins on nonlipid pro-
perties. For example, all statins, except pravastatin,
decreased proliferation of arterial myocytes. The
hydrophilicity of pravastatin could be implicated in
this lack of action due to impaired diffusion of the
drug into extrahepatic cells. Second, chronic meta-
bolic disorders, such as diabetes, might alter, if not
even abolish, antithrombotic actions of statins. Mo-
reover, it is reasonable to hypothesize that since
these effects are not related to lowering of chole-
sterol, also patients with marked hypercholestero-
lemia are likely to benefit from statins. The same
could be true for normolipemic subjects and gives
impetus to studies on the impact of statin treat-
ment in other disorders associated with procoagu-
lant tendency, for example, autoimmune diseases.
Finally, it could be expected that the higher dose
of statin, the more profound are anticoagulant alte-
rations in the blood coagulation cascade.
In summary, statins can impair blood coagulation
at the site of hemostatic plug formation in CAD pa-
tients with hypercholesterolemia. Simvastatin treat-
ment results in a reduced rate of fibrinogen cleava-
ge, FVa generation, and both prothrombin and
FXIII activation and also by faster FVa inactivation
(Fig. 1). Our studies support the concept that ne-
ither the initial lipid profile nor the magnitude of
LDL cholesterol and/or TC reduction after simva-
statin treatment correlate with maximum rates of
the coagulant reactions at sites of hemostatic plug
formation. It is well known that the thrombogenic
response to plaque disruption depends on circula-
ting hemostatic factors, local blood blood condi-
tions, and interactions between blood and the ves-
sel wall. Hence, we believe that antithrombotic ef-
fects here discussed have vital therapeutic implica-
tions and account, at least in part, for the
unquestionable clinical benefits, observed during
treatment with statins.
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